nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisoprolol—CYP3A4—Cytarabine—lymphatic system cancer	0.0571	0.318	CbGbCtD
Bisoprolol—CYP3A4—Teniposide—lymphatic system cancer	0.0562	0.313	CbGbCtD
Bisoprolol—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0393	0.219	CbGbCtD
Bisoprolol—CYP3A4—Vincristine—lymphatic system cancer	0.0271	0.151	CbGbCtD
Bisoprolol—Fatigue—Fludarabine—lymphatic system cancer	0.00184	0.00224	CcSEcCtD
Bisoprolol—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00182	0.00222	CcSEcCtD
Bisoprolol—Hallucination—Vincristine—lymphatic system cancer	0.00182	0.00222	CcSEcCtD
Bisoprolol—Pain—Fludarabine—lymphatic system cancer	0.00182	0.00222	CcSEcCtD
Bisoprolol—Constipation—Fludarabine—lymphatic system cancer	0.00182	0.00222	CcSEcCtD
Bisoprolol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00182	0.00221	CcSEcCtD
Bisoprolol—Vasculitis—Methotrexate—lymphatic system cancer	0.00181	0.00221	CcSEcCtD
Bisoprolol—Respiratory failure—Methotrexate—lymphatic system cancer	0.0018	0.0022	CcSEcCtD
Bisoprolol—Connective tissue disorder—Vincristine—lymphatic system cancer	0.0018	0.00219	CcSEcCtD
Bisoprolol—Eye disorder—Carmustine—lymphatic system cancer	0.00179	0.00219	CcSEcCtD
Bisoprolol—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00179	0.00218	CcSEcCtD
Bisoprolol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00179	0.00218	CcSEcCtD
Bisoprolol—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00178	0.00217	CcSEcCtD
Bisoprolol—Flushing—Carmustine—lymphatic system cancer	0.00178	0.00217	CcSEcCtD
Bisoprolol—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00178	0.00216	CcSEcCtD
Bisoprolol—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00177	0.00216	CcSEcCtD
Bisoprolol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00176	0.00214	CcSEcCtD
Bisoprolol—Asthenia—Teniposide—lymphatic system cancer	0.00174	0.00212	CcSEcCtD
Bisoprolol—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00173	0.00211	CcSEcCtD
Bisoprolol—Malaise—Bleomycin—lymphatic system cancer	0.00173	0.0021	CcSEcCtD
Bisoprolol—Pruritus—Teniposide—lymphatic system cancer	0.00171	0.00209	CcSEcCtD
Bisoprolol—Arrhythmia—Carmustine—lymphatic system cancer	0.00171	0.00209	CcSEcCtD
Bisoprolol—Cystitis—Methotrexate—lymphatic system cancer	0.00171	0.00208	CcSEcCtD
Bisoprolol—Cardiac disorder—Vincristine—lymphatic system cancer	0.0017	0.00207	CcSEcCtD
Bisoprolol—Alopecia—Carmustine—lymphatic system cancer	0.0017	0.00207	CcSEcCtD
Bisoprolol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00168	0.00205	CcSEcCtD
Bisoprolol—Mental disorder—Carmustine—lymphatic system cancer	0.00168	0.00205	CcSEcCtD
Bisoprolol—Erythema—Carmustine—lymphatic system cancer	0.00167	0.00204	CcSEcCtD
Bisoprolol—Cough—Bleomycin—lymphatic system cancer	0.00167	0.00204	CcSEcCtD
Bisoprolol—Angiopathy—Vincristine—lymphatic system cancer	0.00166	0.00203	CcSEcCtD
Bisoprolol—Diarrhoea—Teniposide—lymphatic system cancer	0.00166	0.00202	CcSEcCtD
Bisoprolol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00165	0.00201	CcSEcCtD
Bisoprolol—Chest pain—Bleomycin—lymphatic system cancer	0.00163	0.00199	CcSEcCtD
Bisoprolol—Myalgia—Bleomycin—lymphatic system cancer	0.00163	0.00199	CcSEcCtD
Bisoprolol—Alopecia—Vincristine—lymphatic system cancer	0.00162	0.00197	CcSEcCtD
Bisoprolol—Coma—Methotrexate—lymphatic system cancer	0.00162	0.00197	CcSEcCtD
Bisoprolol—Back pain—Carmustine—lymphatic system cancer	0.00162	0.00197	CcSEcCtD
Bisoprolol—Discomfort—Bleomycin—lymphatic system cancer	0.00161	0.00196	CcSEcCtD
Bisoprolol—Mental disorder—Vincristine—lymphatic system cancer	0.00161	0.00196	CcSEcCtD
Bisoprolol—Urine output increased—Methotrexate—lymphatic system cancer	0.0016	0.00195	CcSEcCtD
Bisoprolol—Bladder pain—Methotrexate—lymphatic system cancer	0.0016	0.00195	CcSEcCtD
Bisoprolol—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00159	0.00194	CcSEcCtD
Bisoprolol—Alopecia—Mitoxantrone—lymphatic system cancer	0.00158	0.00192	CcSEcCtD
Bisoprolol—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00158	0.00192	CcSEcCtD
Bisoprolol—Confusional state—Bleomycin—lymphatic system cancer	0.00157	0.00192	CcSEcCtD
Bisoprolol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00157	0.00191	CcSEcCtD
Bisoprolol—Tremor—Carmustine—lymphatic system cancer	0.00157	0.00191	CcSEcCtD
Bisoprolol—Oedema—Bleomycin—lymphatic system cancer	0.00156	0.0019	CcSEcCtD
Bisoprolol—Erythema—Mitoxantrone—lymphatic system cancer	0.00155	0.00189	CcSEcCtD
Bisoprolol—Infection—Bleomycin—lymphatic system cancer	0.00155	0.00189	CcSEcCtD
Bisoprolol—Back pain—Vincristine—lymphatic system cancer	0.00154	0.00188	CcSEcCtD
Bisoprolol—Vomiting—Teniposide—lymphatic system cancer	0.00154	0.00188	CcSEcCtD
Bisoprolol—Agitation—Carmustine—lymphatic system cancer	0.00154	0.00187	CcSEcCtD
Bisoprolol—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00153	0.00186	CcSEcCtD
Bisoprolol—Asthenia—Fludarabine—lymphatic system cancer	0.00153	0.00186	CcSEcCtD
Bisoprolol—Rash—Teniposide—lymphatic system cancer	0.00153	0.00186	CcSEcCtD
Bisoprolol—Dermatitis—Teniposide—lymphatic system cancer	0.00153	0.00186	CcSEcCtD
Bisoprolol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00152	0.00185	CcSEcCtD
Bisoprolol—Headache—Teniposide—lymphatic system cancer	0.00152	0.00185	CcSEcCtD
Bisoprolol—Pruritus—Fludarabine—lymphatic system cancer	0.00151	0.00184	CcSEcCtD
Bisoprolol—Back pain—Mitoxantrone—lymphatic system cancer	0.0015	0.00183	CcSEcCtD
Bisoprolol—Agitation—Vincristine—lymphatic system cancer	0.00147	0.00179	CcSEcCtD
Bisoprolol—Photosensitivity—Methotrexate—lymphatic system cancer	0.00146	0.00178	CcSEcCtD
Bisoprolol—Polyuria—Methotrexate—lymphatic system cancer	0.00146	0.00178	CcSEcCtD
Bisoprolol—Hypotension—Bleomycin—lymphatic system cancer	0.00146	0.00178	CcSEcCtD
Bisoprolol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00146	0.00178	CcSEcCtD
Bisoprolol—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00144	0.00176	CcSEcCtD
Bisoprolol—Nausea—Teniposide—lymphatic system cancer	0.00144	0.00176	CcSEcCtD
Bisoprolol—Vertigo—Vincristine—lymphatic system cancer	0.00143	0.00175	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00142	0.00173	CcSEcCtD
Bisoprolol—Chest pain—Carmustine—lymphatic system cancer	0.00142	0.00173	CcSEcCtD
Bisoprolol—Myalgia—Carmustine—lymphatic system cancer	0.00142	0.00173	CcSEcCtD
Bisoprolol—Anxiety—Carmustine—lymphatic system cancer	0.00142	0.00173	CcSEcCtD
Bisoprolol—Paraesthesia—Bleomycin—lymphatic system cancer	0.0014	0.00171	CcSEcCtD
Bisoprolol—Malaise—Mitoxantrone—lymphatic system cancer	0.0014	0.00171	CcSEcCtD
Bisoprolol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00139	0.0017	CcSEcCtD
Bisoprolol—Confusional state—Carmustine—lymphatic system cancer	0.00137	0.00168	CcSEcCtD
Bisoprolol—Oedema—Carmustine—lymphatic system cancer	0.00136	0.00166	CcSEcCtD
Bisoprolol—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00136	0.00166	CcSEcCtD
Bisoprolol—Myalgia—Vincristine—lymphatic system cancer	0.00136	0.00166	CcSEcCtD
Bisoprolol—Visual disturbance—Methotrexate—lymphatic system cancer	0.00136	0.00165	CcSEcCtD
Bisoprolol—Cough—Mitoxantrone—lymphatic system cancer	0.00136	0.00165	CcSEcCtD
Bisoprolol—Infection—Carmustine—lymphatic system cancer	0.00135	0.00165	CcSEcCtD
Bisoprolol—Vomiting—Fludarabine—lymphatic system cancer	0.00135	0.00165	CcSEcCtD
Bisoprolol—Rash—Fludarabine—lymphatic system cancer	0.00134	0.00164	CcSEcCtD
Bisoprolol—Dermatitis—Fludarabine—lymphatic system cancer	0.00134	0.00164	CcSEcCtD
Bisoprolol—Pain—Bleomycin—lymphatic system cancer	0.00134	0.00163	CcSEcCtD
Bisoprolol—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00133	0.00163	CcSEcCtD
Bisoprolol—Headache—Fludarabine—lymphatic system cancer	0.00133	0.00163	CcSEcCtD
Bisoprolol—Tachycardia—Carmustine—lymphatic system cancer	0.00133	0.00162	CcSEcCtD
Bisoprolol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00132	0.00161	CcSEcCtD
Bisoprolol—Chest pain—Mitoxantrone—lymphatic system cancer	0.00132	0.00161	CcSEcCtD
Bisoprolol—Myalgia—Mitoxantrone—lymphatic system cancer	0.00132	0.00161	CcSEcCtD
Bisoprolol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00132	0.00161	CcSEcCtD
Bisoprolol—Discomfort—Mitoxantrone—lymphatic system cancer	0.00131	0.00159	CcSEcCtD
Bisoprolol—Oedema—Vincristine—lymphatic system cancer	0.0013	0.00159	CcSEcCtD
Bisoprolol—Infection—Vincristine—lymphatic system cancer	0.00129	0.00158	CcSEcCtD
Bisoprolol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00129	0.00157	CcSEcCtD
Bisoprolol—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00128	0.00157	CcSEcCtD
Bisoprolol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00128	0.00156	CcSEcCtD
Bisoprolol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00128	0.00156	CcSEcCtD
Bisoprolol—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00127	0.00155	CcSEcCtD
Bisoprolol—Hypotension—Carmustine—lymphatic system cancer	0.00127	0.00155	CcSEcCtD
Bisoprolol—Oedema—Mitoxantrone—lymphatic system cancer	0.00127	0.00155	CcSEcCtD
Bisoprolol—Nausea—Fludarabine—lymphatic system cancer	0.00127	0.00154	CcSEcCtD
Bisoprolol—Infection—Mitoxantrone—lymphatic system cancer	0.00126	0.00154	CcSEcCtD
Bisoprolol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00126	0.00153	CcSEcCtD
Bisoprolol—Shock—Mitoxantrone—lymphatic system cancer	0.00125	0.00152	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00124	0.00151	CcSEcCtD
Bisoprolol—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00124	0.00151	CcSEcCtD
Bisoprolol—Urticaria—Bleomycin—lymphatic system cancer	0.00124	0.00151	CcSEcCtD
Bisoprolol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00124	0.00151	CcSEcCtD
Bisoprolol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00123	0.00151	CcSEcCtD
Bisoprolol—Insomnia—Carmustine—lymphatic system cancer	0.00123	0.0015	CcSEcCtD
Bisoprolol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00123	0.0015	CcSEcCtD
Bisoprolol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00123	0.00149	CcSEcCtD
Bisoprolol—Paraesthesia—Carmustine—lymphatic system cancer	0.00122	0.00149	CcSEcCtD
Bisoprolol—Mood swings—Methotrexate—lymphatic system cancer	0.00122	0.00148	CcSEcCtD
Bisoprolol—Hypotension—Vincristine—lymphatic system cancer	0.00122	0.00148	CcSEcCtD
Bisoprolol—Dyspnoea—Carmustine—lymphatic system cancer	0.00122	0.00148	CcSEcCtD
Bisoprolol—Somnolence—Carmustine—lymphatic system cancer	0.00121	0.00148	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00119	0.00145	CcSEcCtD
Bisoprolol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00118	0.00144	CcSEcCtD
Bisoprolol—Insomnia—Vincristine—lymphatic system cancer	0.00118	0.00144	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00118	0.00143	CcSEcCtD
Bisoprolol—Paraesthesia—Vincristine—lymphatic system cancer	0.00117	0.00142	CcSEcCtD
Bisoprolol—Pain—Carmustine—lymphatic system cancer	0.00117	0.00142	CcSEcCtD
Bisoprolol—Constipation—Carmustine—lymphatic system cancer	0.00117	0.00142	CcSEcCtD
Bisoprolol—Breast disorder—Methotrexate—lymphatic system cancer	0.00116	0.00142	CcSEcCtD
Bisoprolol—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00116	0.00141	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00115	0.00141	CcSEcCtD
Bisoprolol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00115	0.0014	CcSEcCtD
Bisoprolol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00114	0.00139	CcSEcCtD
Bisoprolol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00113	0.00138	CcSEcCtD
Bisoprolol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00113	0.00137	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00112	0.00137	CcSEcCtD
Bisoprolol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00112	0.00137	CcSEcCtD
Bisoprolol—Fatigue—Vincristine—lymphatic system cancer	0.00112	0.00137	CcSEcCtD
Bisoprolol—Asthenia—Bleomycin—lymphatic system cancer	0.00112	0.00137	CcSEcCtD
Bisoprolol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00112	0.00136	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00111	0.00136	CcSEcCtD
Bisoprolol—Pain—Vincristine—lymphatic system cancer	0.00111	0.00136	CcSEcCtD
Bisoprolol—Constipation—Vincristine—lymphatic system cancer	0.00111	0.00136	CcSEcCtD
Bisoprolol—Asthma—Methotrexate—lymphatic system cancer	0.00111	0.00135	CcSEcCtD
Bisoprolol—Pruritus—Bleomycin—lymphatic system cancer	0.00111	0.00135	CcSEcCtD
Bisoprolol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00109	0.00133	CcSEcCtD
Bisoprolol—Pain—Mitoxantrone—lymphatic system cancer	0.00108	0.00132	CcSEcCtD
Bisoprolol—Constipation—Mitoxantrone—lymphatic system cancer	0.00108	0.00132	CcSEcCtD
Bisoprolol—Abdominal pain—Carmustine—lymphatic system cancer	0.00108	0.00131	CcSEcCtD
Bisoprolol—Body temperature increased—Carmustine—lymphatic system cancer	0.00108	0.00131	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00106	0.0013	CcSEcCtD
Bisoprolol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00104	0.00127	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00104	0.00126	CcSEcCtD
Bisoprolol—Body temperature increased—Vincristine—lymphatic system cancer	0.00103	0.00125	CcSEcCtD
Bisoprolol—Abdominal pain—Vincristine—lymphatic system cancer	0.00103	0.00125	CcSEcCtD
Bisoprolol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00102	0.00125	CcSEcCtD
Bisoprolol—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00101	0.00124	CcSEcCtD
Bisoprolol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00101	0.00123	CcSEcCtD
Bisoprolol—Hypersensitivity—Carmustine—lymphatic system cancer	0.001	0.00122	CcSEcCtD
Bisoprolol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.001	0.00122	CcSEcCtD
Bisoprolol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.001	0.00122	CcSEcCtD
Bisoprolol—Pneumonia—Methotrexate—lymphatic system cancer	0.000996	0.00121	CcSEcCtD
Bisoprolol—Vomiting—Bleomycin—lymphatic system cancer	0.000993	0.00121	CcSEcCtD
Bisoprolol—Drowsiness—Methotrexate—lymphatic system cancer	0.00099	0.00121	CcSEcCtD
Bisoprolol—Depression—Methotrexate—lymphatic system cancer	0.000987	0.0012	CcSEcCtD
Bisoprolol—Rash—Bleomycin—lymphatic system cancer	0.000985	0.0012	CcSEcCtD
Bisoprolol—Dermatitis—Bleomycin—lymphatic system cancer	0.000984	0.0012	CcSEcCtD
Bisoprolol—Asthenia—Carmustine—lymphatic system cancer	0.000978	0.00119	CcSEcCtD
Bisoprolol—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000963	0.00117	CcSEcCtD
Bisoprolol—Hypersensitivity—Vincristine—lymphatic system cancer	0.000959	0.00117	CcSEcCtD
Bisoprolol—Sweating—Methotrexate—lymphatic system cancer	0.000949	0.00116	CcSEcCtD
Bisoprolol—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000936	0.00114	CcSEcCtD
Bisoprolol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000934	0.00114	CcSEcCtD
Bisoprolol—Asthenia—Vincristine—lymphatic system cancer	0.000934	0.00114	CcSEcCtD
Bisoprolol—Diarrhoea—Carmustine—lymphatic system cancer	0.000933	0.00114	CcSEcCtD
Bisoprolol—Nausea—Bleomycin—lymphatic system cancer	0.000928	0.00113	CcSEcCtD
Bisoprolol—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000924	0.00113	CcSEcCtD
Bisoprolol—Asthenia—Mitoxantrone—lymphatic system cancer	0.000909	0.00111	CcSEcCtD
Bisoprolol—Dizziness—Carmustine—lymphatic system cancer	0.000902	0.0011	CcSEcCtD
Bisoprolol—Diarrhoea—Vincristine—lymphatic system cancer	0.000891	0.00109	CcSEcCtD
Bisoprolol—Hepatitis—Methotrexate—lymphatic system cancer	0.000889	0.00108	CcSEcCtD
Bisoprolol—Pharyngitis—Methotrexate—lymphatic system cancer	0.000882	0.00108	CcSEcCtD
Bisoprolol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000867	0.00106	CcSEcCtD
Bisoprolol—Vomiting—Carmustine—lymphatic system cancer	0.000867	0.00106	CcSEcCtD
Bisoprolol—Dizziness—Vincristine—lymphatic system cancer	0.000861	0.00105	CcSEcCtD
Bisoprolol—Rash—Carmustine—lymphatic system cancer	0.00086	0.00105	CcSEcCtD
Bisoprolol—Dermatitis—Carmustine—lymphatic system cancer	0.000859	0.00105	CcSEcCtD
Bisoprolol—Visual impairment—Methotrexate—lymphatic system cancer	0.000857	0.00104	CcSEcCtD
Bisoprolol—Headache—Carmustine—lymphatic system cancer	0.000854	0.00104	CcSEcCtD
Bisoprolol—Eye disorder—Methotrexate—lymphatic system cancer	0.000831	0.00101	CcSEcCtD
Bisoprolol—Tinnitus—Methotrexate—lymphatic system cancer	0.000829	0.00101	CcSEcCtD
Bisoprolol—Vomiting—Vincristine—lymphatic system cancer	0.000828	0.00101	CcSEcCtD
Bisoprolol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000825	0.00101	CcSEcCtD
Bisoprolol—Rash—Vincristine—lymphatic system cancer	0.000821	0.001	CcSEcCtD
Bisoprolol—Dermatitis—Vincristine—lymphatic system cancer	0.00082	0.001	CcSEcCtD
Bisoprolol—Headache—Vincristine—lymphatic system cancer	0.000815	0.000994	CcSEcCtD
Bisoprolol—Nausea—Carmustine—lymphatic system cancer	0.00081	0.000987	CcSEcCtD
Bisoprolol—Angiopathy—Methotrexate—lymphatic system cancer	0.000807	0.000983	CcSEcCtD
Bisoprolol—Vomiting—Mitoxantrone—lymphatic system cancer	0.000806	0.000982	CcSEcCtD
Bisoprolol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000801	0.000977	CcSEcCtD
Bisoprolol—Rash—Mitoxantrone—lymphatic system cancer	0.000799	0.000974	CcSEcCtD
Bisoprolol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000798	0.000973	CcSEcCtD
Bisoprolol—Headache—Mitoxantrone—lymphatic system cancer	0.000794	0.000968	CcSEcCtD
Bisoprolol—Alopecia—Methotrexate—lymphatic system cancer	0.000786	0.000958	CcSEcCtD
Bisoprolol—Mental disorder—Methotrexate—lymphatic system cancer	0.000779	0.000949	CcSEcCtD
Bisoprolol—Erythema—Methotrexate—lymphatic system cancer	0.000774	0.000943	CcSEcCtD
Bisoprolol—Nausea—Vincristine—lymphatic system cancer	0.000773	0.000942	CcSEcCtD
Bisoprolol—Dysgeusia—Methotrexate—lymphatic system cancer	0.000758	0.000924	CcSEcCtD
Bisoprolol—Nausea—Mitoxantrone—lymphatic system cancer	0.000753	0.000918	CcSEcCtD
Bisoprolol—Back pain—Methotrexate—lymphatic system cancer	0.000749	0.000912	CcSEcCtD
Bisoprolol—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000718	0.000875	CcSEcCtD
Bisoprolol—Malaise—Methotrexate—lymphatic system cancer	0.000698	0.000851	CcSEcCtD
Bisoprolol—Vertigo—Methotrexate—lymphatic system cancer	0.000695	0.000848	CcSEcCtD
Bisoprolol—Cough—Methotrexate—lymphatic system cancer	0.000675	0.000823	CcSEcCtD
Bisoprolol—Myalgia—Methotrexate—lymphatic system cancer	0.000659	0.000803	CcSEcCtD
Bisoprolol—Arthralgia—Methotrexate—lymphatic system cancer	0.000659	0.000803	CcSEcCtD
Bisoprolol—Chest pain—Methotrexate—lymphatic system cancer	0.000659	0.000803	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000654	0.000798	CcSEcCtD
Bisoprolol—Discomfort—Methotrexate—lymphatic system cancer	0.000651	0.000793	CcSEcCtD
Bisoprolol—Confusional state—Methotrexate—lymphatic system cancer	0.000637	0.000776	CcSEcCtD
Bisoprolol—Infection—Methotrexate—lymphatic system cancer	0.000627	0.000765	CcSEcCtD
Bisoprolol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000619	0.000755	CcSEcCtD
Bisoprolol—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000618	0.000754	CcSEcCtD
Bisoprolol—Skin disorder—Methotrexate—lymphatic system cancer	0.000613	0.000748	CcSEcCtD
Bisoprolol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000611	0.000744	CcSEcCtD
Bisoprolol—Hypotension—Methotrexate—lymphatic system cancer	0.00059	0.000719	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000575	0.000701	CcSEcCtD
Bisoprolol—Insomnia—Methotrexate—lymphatic system cancer	0.000571	0.000696	CcSEcCtD
Bisoprolol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000567	0.000691	CcSEcCtD
Bisoprolol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000563	0.000686	CcSEcCtD
Bisoprolol—Somnolence—Methotrexate—lymphatic system cancer	0.000561	0.000684	CcSEcCtD
Bisoprolol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000556	0.000678	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000545	0.000665	CcSEcCtD
Bisoprolol—Fatigue—Methotrexate—lymphatic system cancer	0.000544	0.000664	CcSEcCtD
Bisoprolol—Pain—Methotrexate—lymphatic system cancer	0.00054	0.000658	CcSEcCtD
Bisoprolol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00052	0.000634	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000516	0.00063	CcSEcCtD
Bisoprolol—Urticaria—Methotrexate—lymphatic system cancer	0.000502	0.000612	CcSEcCtD
Bisoprolol—Body temperature increased—Methotrexate—lymphatic system cancer	0.000499	0.000609	CcSEcCtD
Bisoprolol—Abdominal pain—Methotrexate—lymphatic system cancer	0.000499	0.000609	CcSEcCtD
Bisoprolol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000465	0.000567	CcSEcCtD
Bisoprolol—Asthenia—Methotrexate—lymphatic system cancer	0.000453	0.000552	CcSEcCtD
Bisoprolol—Pruritus—Methotrexate—lymphatic system cancer	0.000447	0.000545	CcSEcCtD
Bisoprolol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000432	0.000527	CcSEcCtD
Bisoprolol—Dizziness—Methotrexate—lymphatic system cancer	0.000418	0.000509	CcSEcCtD
Bisoprolol—Vomiting—Methotrexate—lymphatic system cancer	0.000402	0.00049	CcSEcCtD
Bisoprolol—Rash—Methotrexate—lymphatic system cancer	0.000398	0.000485	CcSEcCtD
Bisoprolol—Dermatitis—Methotrexate—lymphatic system cancer	0.000398	0.000485	CcSEcCtD
Bisoprolol—Headache—Methotrexate—lymphatic system cancer	0.000396	0.000482	CcSEcCtD
Bisoprolol—Nausea—Methotrexate—lymphatic system cancer	0.000375	0.000457	CcSEcCtD
